$ABVX

Piper Sandler reiterated an Overweight rating and $175 price target for Abivax (ABVX) after positive trial data. The firm highlighted obefazimod's strong endoscopic-remission profile in inflammatory bowel disease. ABVX shares have fallen 30% since August, trading at $94.21. Analysts' price targets range from $142 to $181. Goldman Sachs initiated coverage with a Buy rating and $155 target, citing obefazimod's potential in ulcerative colitis.

Abivax (Euronext: ABVX, Nasdaq: ABVX) will present data on obefazimod, its lead drug for ulcerative colitis, at UEG Week 2026. The presentations include Phase 3 and Phase 2 trial results, and preclinical research. The company's CEO and CMO highlighted the potential of obefazimod in treating inflammatory bowel disease.

ABIVAX (ABVX) reported a 54% increase in operating cash use to €102.5M in H1 2026, with €1.2B in total liquidity post-equity financing. The company projects funds will last until Q4 2029, supporting its planned U.S. drug application for obefazimod by year-end. Investors focus on spending efficiency and regulatory progress.

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.

Abivax S.A. (ABVX) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Abivax Presents Business Updates and First Half 2026 Financial Results • Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax’s Chemistry, Manufacturing and

Abivax (ABVX) is expected to report a first-half loss of $1.08 per share on revenue of $1.86M. Marygold (MGLD) and Neuphoria (NEUP) reported Q4 losses. Accenture (ACN) partnered with Anthropic, shares up 8.1%. Lobo (LOBO) reported H1 growth, shares up 26.7%.

Analysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.

Analysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.

Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.

EQS-News: ABIVAX / Key word(s): Regulatory Admission Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod 30.07.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement.